Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.

<p>Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.</p>


Kinevant Sciences

Buckling down on HBV hopeful, Arbutus slashes more than half its workforce - FirstWord

Pulmonary Sarcoidosis Market Insight 2032: Clinical Trials, - openPR.com


                Episode 131| The second best outcome in a clinical trial is one that didn't work.
              


                                                Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis 
                                            

Roivant spinout ends development of lung disease asset after phase 2 fail - Fierce Biotech


                                                Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung) 
                                            

 Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis 

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha

Online home spirometry in national pulmonary fibrosis care: insights from daily practice - ERS - European Respiratory Society

Kinevant doses first patient in Phase II pulmonary sarcoidosis trial - Clinical Trials Arena


                                                Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis 
                                            

Veklury Reduces Mortality in Immunocompromised People With COVID-19 - Infectious Disease Special Edition


                                                            Listen on Apple Podcasts
                                                        

Great seeing both familiar and new faces yesterday at the FDA Patient-led Drug Development Meeting on Sarcoidosis hosted by the Foundation For Sarcoidosis Research!  We are proud to sponsor this important initiative and are grateful for the many patients and caregivers who shared their experiences living with sarcoidosis to help inform drug development.

https://lnkd.in/gQGMR_MQ

Sarcoidosis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences - Barchart

Development to stop on namilumab as pulmonary sarcoidosis treatment - Sarcoidosis News

Very excited to welcome Tim to our leadership team at Kinevant on Rare Disease Disease! Tim is bringing significant program leadership to the development of a new therapy for patients suffering from pulmonary sarcoidosis and potentially other rare autoimmune and inflammatory diseases. 


              Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
            

We're thrilled to announce that Hajira Koeller, PhD has joined the Kinevant team as Senior Director, Clinical Research Scientist. With over 15 years of experience in neurology, psychiatry, and rare diseases, Hajira brings a wealth of knowledge and expertise to our team. 
 
Her background in clinical development, medical affairs, and scientific communications makes her a valuable addition as we continue to explore the new potential therapies for rare #autoimmune and #inflammatory diseases and support our work to help people living with #PulmonarySarcoidosis. 
 
Welcome to the team, Hajira Koeller, PhD! 
 
#NewEmployeeSpotlight 

symbol__ Stock Quote Price and Forecast - CNN


                                                Kinevant Sciences makes progress with its drug Namilumab 
                                            

Pulmonary Sarcoidosis Market Set to Experience Significant - openPR.com

Harmony, Lungpacer, Verrica and Arbutus make C-suite hires - The Business Journals

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis - The Manila Times

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MyChesCo

 Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for ... 

Please join us in welcoming Tim Noffke to our leadership team as Vice President, Program Management! Tim’s more than 25 years of experience leading multiple projects and programs across diverse therapeutic areas in the biopharma industry will support our ability to efficiently advance namilumab, our investigational, novel fully human monoclonal antibody designed to improve the lives of those with autoimmune and inflammatory diseases.
#NewEmployeeSpotlight

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis - The Manila Times

 Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis 

 Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update 

Phase 2 trial data of namilumab for pulmonary sarcoidosis slated... - Sarcoidosis News

Roivant Sciences and Kinevant Sciences today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung). Topline results are expected by the end of calendar year 2024.

“I am grateful for the patients who volunteered to participate in the study, as well as for the extraordinary efforts of the Kinevant team, our industry partners, clinical trial site staff, and patient advocacy groups, all of whom came together to overcome the unique challenges of this disease to successfully enroll this study.” – Bill Gerhart, CEO

For access to the full press release, please visit: https://lnkd.in/djDFMzxt

#sarcoidosis
#pulmonarysarcoidosis
#sarcoidosisawarenessmonth
#raredisease

Roivant plans to launch Phase 2 trial of brepocitinib in cutaneous... - Sarcoidosis News

OUT NOW! FSR Sarc Fighter Podcast Episode 113 – Kinevant Sciences makes progress with its drug namilumab, announcing completing enrollment for RESOLVE-Lung.
 
Hear from Kinevant CEO Bill Gerhart and Head of Patient Advocacy Rayne Rodgers, MPH as we join John Carlin, host of the Foundation For Sarcoidosis Research Sarc Fighter Podcast, to discuss an important milestone in researching namilumab for chronic pulmonary sarcoidosis.
 
 Available wherever you get your podcasts or here: https://lnkd.in/g6_bh942 
 
 #sarcoidosis 
 #pulmonarysarcoidosis 
 #sarcoidosisawarenessmonth 
 #resolve 
 #resolvelung 
 #raredisease 
 #rarediseaseawareness

Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study - MarketWatch

Kinevant Sciences presented today the trial design and baseline patient characteristics for our Ph II pulmonary sarcoidosis trial at the European Respiratory Society (#ERS2024) Congress in Vienna, Austria.  The oral presentation entitled “RESOLVE-Lung, a multinational Phase II, randomized, placebo-controlled trial of namilumab in chronic pulmonary sarcoidosis: Trial design and patient characteristics” was given by Dr. Bernt van den Blink, our Head of Clinical Development at Kinevant.

Please find the accompanying e-poster available here: https://lnkd.in/g2qwU_xG

The RESOLVE-Lung study was fully enrolled earlier this year as previously announced, and topline results are expected by the end of this year.

Sarcoidosis is a systemic inflammatory disease that most commonly affects the lungs. Chronic pulmonary sarcoidosis affects approximately 100,000 people in the U.S. and is characterized by unremitting cough, chest pain, breathlessness, and declining lung function. In some patients, persistent inflammation results in lung fibrosis that can lead to lung failure or the need for transplantation. 

RESOLVE-Lung was designed to evaluate our investigational anti-GM-CSF monoclonal antibody candidate, namilumab, in patients not well controlled despite receiving commonly used therapies to treat pulmonary sarcoidosis (oral corticosteroids [OCS], or immunosuppressive therapies [IST] used off-label). These medicines are often not effective and/or result in unacceptable side effects. There exists a significant unmet need for a new therapy that is both effective and well-tolerated. 

In the RESOLVE-Lung trial, we are utilizing a novel primary endpoint: % of patients requiring a Rescue Event during the six-month double-blind treatment period (namilumab vs placebo). As is evident from the baseline patient characteristics, all patients enrolled in the study had evidence of active disease despite the availability of OCS and/or IST. For a heterogeneous disease such as pulmonary sarcoidosis, the need for rescue relating to the worsening of their disease may be the most sensitive assessment of how patients are feeling and functioning.

We are grateful for the patients who volunteered to participate in the study, as well as the clinical trial site staff and patient advocacy groups who have facilitated and supported this important clinical research in sarcoidosis.

Roivant Phase II miss for namilumab - The Pharma Letter

Kinevant's namilumab fails to deliver in pulmonary sarcoidosis - FirstWord Pharma

Trial of namilumab for pulmonary sarcoidosis now fully enrolled - Sarcoidosis News

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis - Business Wire

Pulmonary Sarcoidosis Market to Reach New Heights in Growth - openPR.com

Kinevant Sciences

Business:

About: